MedTrace Logo

Treatment of Non-falciparum Malaria

NCT00725777 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-02-17

No results posted yet for this study

Summary

Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.

Conditions

  • Acute Non-falciparum Malaria

Interventions

DRUG

artemether-lumefantrine

Standard artemether-lumefantrine treatment

Sponsors & Collaborators

  • Albert Schweitzer Hospital

    lead OTHER

Principal Investigators

  • Sabine Bélard, MD · Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-12-31
Completion
2012-02-29

Countries

  • Gabon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725777 on ClinicalTrials.gov